TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A

Yi Zhang¹, Ran Tao², Shan-Shan Wu¹, Cui-Cui Xu¹, Jie-Ling Wang³, Jie Chen¹, Yong-Sheng Yu¹, Zheng-Hao Tang¹, Xiao-Hua Chen¹* and Guo-Qing Zang¹*

Abstract

Background: Many tripartite motif (TRIM) family proteins have been reported to be of great importance in the initiation and progression in hepatocellular carcinoma (HCC). However, the biological role and regulatory mechanism of tripartite motif containing 52 (TRIM52) in HCC development and progression are poorly defined.

Methods: Immunohistochemistry (IHC), quantitative real-time PCR (qRT-PCR) or Western blot analysis was used to detect TRIM52, p21, matrix metalloproteinase 2 (MMP2), protein phosphatase, Mg²⁺/Mn²⁺ dependent 1A (PPM1A), p-Smad2/3 and Smad2/3 levels in HCC tissues and cell lines. HCC cell proliferation and cell cycle were measured by Cell Counting Kit-8 (CCK-8) and flow cytometry analysis, respectively. HCC cell migration and invasion were measured by Transwell assay. Tumor growth of HCC cells in vivo was measured using the nude mouse xenograft model. The correlation between TRIM52 and PPM1A was measured by co-immunoprecipitation (Co-IP) and ubiquitination analysis in vitro.

Results: TRIM52 was significantly up-regulated in the HCC tissues in comparison with the adjacent non-tumor hepatic tissues. TRIM52 was also up-regulated in HCC cell lines (MHCC-97H and MHCC-97L cells) compared with normal human liver cell line LO2. TRIM52 down-regulation by RNA interfering in MHCC-97H cells enhanced inhibition of cell proliferation, migration and invasion. TRIM52 down-regulation also induced MHCC-97H cells arrest in G0-G1 phase cell cycle and inhibited MHCC-97H cell growth in the nude mice. However, TRIM52 up-regulation in MHCC-97L cells promoted cell proliferation, migration and invasion. Furthermore, TRIM52 down-regulation significantly increased p21 and PPM1A expression, but inhibited MMP2 expression and induced Smad2/3 dephosphorylation in MHCC-97H cells, which were reversed by TRIM52 up-regulation in MHCC-97L cells. TRIM52 was found interacted with PPM1A and TRIM52 down-regulation inhibited the ubiquitination of PPM1A. Importantly, PPM1A up-regulation in MHCC-97L cells significantly suppressed TRIM52-mediated enhancement on cell proliferation, invasion and migration.

Conclusions: Our findings suggest that TRIM52 up-regulation promotes proliferation, migration and invasion of HCC cells through the ubiquitination of PPM1A.

Keywords: Hepatocellular carcinoma, TRIM52, PPM1A, Ubiquitination

* Correspondence: chenxiaohua2000@163.com; zangguoqin@126.com
1Department of Infectious Diseases, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai 200233, China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hepatocellular carcinoma (HCC) is one of the most common malignant primary liver tumors and is the third leading cause of global cancer death, particularly in East Asia and South Africa [1]. Like other cancers, HCC is involved in a complex and multistep process which is related to a variety of genetic and epigenetic changes. Although many efforts have been made, one of the major problems with HCC is that there are no obvious symptoms, so most patients with HCC are only diagnosed at an advanced stage, and the patients’ survival rates are therefore discouraging [2, 3]. Cirrhosis caused by hepatitis B virus (HBV) or hepatitis C virus (HCV) is reported to be associated with HCC [4]. At present, nonalcoholic fatty liver disease is becoming the leading cause of HCC, and there are no ideal targeted therapies [5]. Additionally, it was also found that oncogenes and/or loss of tumor suppressor genes could be potential biomarkers, as the dysregulated expression level was associated with clinicopathologic characteristics, even prognosis [6, 7]. However, little is known about the molecular and cellular mechanisms. Understanding the mechanisms underlying key genes is essential for further clarifying the pathogenesis of HCC and can provide opportunities for the development of novel therapeutic strategies.

Protein phosphatase, Mg2+/Mn2+ dependent 1A (PPM1A) is a member of the protein phosphatase 2C (PP2C) family of serine/threonine protein phosphatases, which negatively regulate the cellular stress response pathway [8]. Overexpression of PPM1A can activate the expression of p53 and its downstream p21, which are tumor suppressor genes in cancer development, leading to G2-M phase cell cycle arrest as well as apoptosis, and may be involved in the regulation of tumor pathogenesis [9]. PPM1A can dephosphorylate Smad1, thereby regulating the signaling pathway of bone morphogenetic protein (BMP) in transforming growth factor-β (TGF-β) superfamily [10]. PPM1A can also specifically terminate the TGF-β signaling pathway by dephosphorylation of Smad2/3, which has expanded the substrate type of PPM1A and its signaling pathways [11]. It has been found that PPM1A was downregulated in the HCC tissues compared with the corresponding pericarcinous tissues and that down-regulation of PPM1A through increasing its proteasomal degradation and ubiquitination resulted in the increased ability of HCC cell migration and invasion [12, 13].

Ubiquitination is an important post-translational modification and E3 ubiquitin ligase plays an important role in ubiquitination [14]. Tripartite motif (TRIM) family proteins are considered as E3 ubiquitin ligase with more than 80 members and are associated with developmental disorders, neurodegenerative diseases and viral infections as well as cancer cell growth and differentiation through regulating cell proliferation and apoptosis [15–17]. Tripartite motif containing 52 (TRIM52) is a novel TRIM family protein. A previous study demonstrated that TRIM52 inhibited Japanese encephalitis virus (JEV) replication by degrading the viral nonstructural protein 2A (NS2A) [18]. Additionally, TRIM52 promotes HCC cell proliferation in HBV-associated HCC and HBV X protein (HBx) may regulate TRIM52 expression via the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway [19]. However, the function of TRIM52 in regulating cell cycle and motility of HCC is still largely not understood.

In this study, we have identified that TRIM52 up-regulation in HCC and promote HCC cell proliferation, migration and invasion. Our data suggest that ubiquitination of PPM1A by TRIM52 may be a novel mechanism underlying HCC carcinogenesis.

Methods
Study subjects
The human HCC tissue microarrays used in this study were prepared by Shanghai Outdo Biotech Co., Ltd. (Shanghai, China). The clinicopathologic characteristics of the 87 patients enrolled in the study are summarized in Table 1. This study was approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital.

Immunohistochemistry (IHC) analysis
After deparaffinization, rehydration and antigen-retrieval, hepatic tissue slides (4–7 μm) were blocked by 3% H2O2 for 10 min and incubated with anti-Ki67, anti-p-Smad2/3 and anti-MMP2 antibody (Abcam, Cambridge, MA, USA) at 4 °C overnight. The slides were then stained with horse-radish peroxidase (HRP)-labeled IgG (Shanghai Long Island Biotec, Shanghai, China) at 25 °C. Subsequently, the sections were washed with diaminobenzidine (DAB), counterstained with hematoxylin and washed in water. The immunoreactive cells were counted in five visual fields of each section under a 200 × light microscope.

Cell culture and transfection
Human high metastatic HCC cell line MHCC-97H and low metastatic HCC cell line MHCC-97L, and immortalized normal human liver cell line LO2 were obtained from ATCC (Manassas, VA, USA) and cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Logan, UT, USA) complemented with 10% fetal bovine serum (FBS) (Gibco, Detroit, MI, USA) along with 1% Penicillin-Streptomycin solution separately incubated in 37 °C with 5% CO2 and 95% air. Oligonucleotides encoding short hairpin RNA (shRNA) targeting human TRIM52 (point 670–692,
5′-GGGCATGTGCTTTAAACAC-3′) and scramble shRNA were cloned into the pLKO.1 lentiviral vector. The cDNA encoding TRIM52 and PPM1A was obtained by reverse transcription PCR (RT-PCR) and cloned into pLVX-Puro for constructing pLVX-Puro-TRIM52 and pLVX-Puro-PPM1A expressing vector, respectively. pLKO.1-scramble shRNA (NC) and blank pLVX-Puro (Vector) were used as the negative controls. 293T cells were plated in 6-well plates and transfected with constructs for 4–6 h using Lipofectamine Reagent (Invitrogen, Carlsbad, CA, USA) according to the instructions of the manufacturer. After incubation in a CO₂ incubator at 37 °C, recombined lentivirus was collected 48 h after transfection and used for MHCC-97H and MHCC-97L cells infection.

### Table 1

| Parameters                          | Total number of the patients (N = 87) |
|-------------------------------------|--------------------------------------|
| Age (years)                         |                                      |
| ≤53                                 | 47 (54.0%)                           |
| > 53                                | 40 (46.0%)                           |
| Sex                                 |                                      |
| Female                              | 8 (9.2%)                             |
| Male                                | 79 (90.8%)                           |
| Tumor size (cm)                     |                                      |
| ≤4                                  | 25 (28.7%)                           |
| > 4                                 | 62 (71.3%)                           |
| Recurrence (2 years)                |                                      |
| Yes                                 | 63 (72.4%)                           |
| No                                  | 24 (27.6%)                           |
| Differentiation                     |                                      |
| Low                                 | 39 (44.8%)                           |
| Moderate                            | 38 (43.7%)                           |
| High                                | 10 (11.5%)                           |
| Tumor number                        |                                      |
| Single                              | 64 (73.6%)                           |
| Multiple                            | 23 (26.4%)                           |
| TNM stages                          |                                      |
| I                                   | 15 (17.2%)                           |
| II                                  | 22 (25.3%)                           |
| III                                 | 20 (23.0%)                           |
| IV                                  | 30 (34.5%)                           |
| Pathologic stages                   |                                      |
| I                                   | 6 (6.9%)                             |
| II                                  | 34 (39.1%)                           |
| III                                 | 40 (46.0%)                           |
| IV                                  | 7 (8.0%)                             |
| Lung metastasis                     |                                      |
| Yes                                 | 16 (18.4%)                           |
| No                                  | 71 (81.6%)                           |
| HBsAg                               |                                      |
| Negative                            | 7 (8.0%)                             |
| Positive                            | 80 (92.0%)                           |
| HBV infection                       |                                      |
| Absent                              | 7 (8.0%)                             |
| Present                             | 80 (92.0%)                           |

HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus

### Cell proliferation

After indicated transfection, MHCC-97H and MHCC-97L cells (4 × 10³ cells/well) were plated in 96-well plates and cultured for 0, 24, 48 and 72 h, and the cells were added with 10 μL Cell Counting Kit-8 (CCK-8) solution (Signalway Antibody, College Park, MD, USA) with 5% CO₂ at 37 °C for 1 h, after which the absorbance readings were obtained at 450 nm.

### Cell cycle

Propidium iodide (PI) staining was performed in MHCC-97H and MHCC-97L cells. Briefly, the cells were trypsinized, resuspended in phosphate buffer solution (PBS) containing 10% FBS and fixed in 70% chilled ethanol before cultured in 10 mmol/L RNase at 37 °C for 10 min. After 5 min centrifugation at 1000xg, the cells were resuspended with RNase A (1 mg/mL) for 30 min. Then PI (50 μg/mL) was added in the cells for 10 min at 37 °C under dark. The fluorescence intensities were assessed by flow cytometer (BD Biosciences, San Jose, CA, USA).

### Transwell assay

The invasive ability of MHCC-97H and MHCC-97L cells to pass through filters was measured using a Transwell insert coated with Matrigel. Briefly, MHCC-97H and MHCC-97L cells transfected with indicated lentivirus vectors were serum-starved for 24 h, following which 5 × 10³ cells/well in 300 μL serum-free DMEM were placed in the upper chamber at 37 °C. The DMEM medium containing 10% FBS (700 μL) was added into the lower chamber. After 48 h incubation, the cells migrated through to the bottom surface of the membrane were washed with PBS, fixed, stained with 0.5% crystal violet and counted. The invasive cells found on the bottom site of each inserts were then photographed and counted under a microscope (× 200; Olympus, Tokyo, Japan). The migratory ability of MHCC-97H and MHCC-97L cells was measured using Transwell without Matrigel coated.
Quantitative real-time PCR (qRT-PCR)
Whole RNA was extracted from the HCC cell lines by using TRIzol reagent (Invitrogen) and stored at −80 °C in RNA secure RNase Inactivation Reagent (Thermo Fisher, St. Louis, MO, USA), and PrimeScript reverse-transcription reagent Kit (Thermo Fisher) was used to carry out reverse transcription reaction on RNA in accordance with the protocols of the manufacturer. Quantitative analysis on the change in expression level was conducted by SYBR Green qPCR Master Mixes (Thermo Fisher) and performed using the GeneAmp PCR System 2700 (Applied Biosystems, Foster City, CA, USA). The primer sequences were shown subsequently:

TRIM52 forward: 5'-GCCATCTGCTTGGATTACTTC-3';
TRIM52 reverse: 5'-TTCATCTTCCTCCTCGTTCTG-3';
PPM1A forward: 5'-CCCTTGTTTTCTCTACTTTT-3';
PPM1A reverse: 5'-TAATCCCTTCTCTCATTCC-3';
GAPDH forward: 5'-AATCCCATCACCACCTCTTC-3';
GAPDH reverse: 5'-AGGCTTGTTGTCACTTTG-3'.

The change in the expression of mRNA was assessed by the 2^{-ΔΔCt} approach.

Western blot assay
Total protein extraction was performed with RIPA Lysis Buffer (Solarbio, Beijing, China) and then centrifuged at 12,000×g for 10 min. Proteins in cell lysates were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes (Millipore, Bedford, MA, USA), then incubated into TRIM52,
p21, matrix metalloproteinase 2 (MMP2), PPM1A, p-Smad2/3, Smad2/3 or GAPDH antibodies overnight at 4 °C. The next day, the membranes were washed and subsequently incubated with HRP-conjugated secondary antibodies (1:1000; Beyotime, Nanjing, Jiangsu, China) for 1 h at 37 °C. Then, the membranes were

| Parameters              | TRIM52 | \( P \) value |
|-------------------------|--------|---------------|
|                        | Low group, number of the patients | High group, number of the patients |
| Age (years)            |        | 0.6598        |
| \( \leq 53 \)           | 21     | 26            |
| \( > 53 \)              | 16     | 24            |
| Sex                     |        | 0.7267        |
| Female                  | 3      | 5             |
| Male                    | 34     | 45            |
| Tumor size (cm)         |        | 0.0363        |
| \( \leq 4 \)            | 15     | 10            |
| \( > 4 \)               | 22     | 40            |
| Recurrence (2 years)    |        | 0.1754        |
| Yes                     | 24     | 39            |
| No                      | 13     | 11            |
| TNM stages              |        | < 0.0001      |
| I                       | 12     | 3             |
| II                      | 14     | 8             |
| III                     | 4      | 16            |
| IV                      | 7      | 23            |
| Pathologic stages       |        | 0.2267        |
| I                       | 3      | 3             |
| II                      | 18     | 16            |
| III                     | 15     | 25            |
| IV                      | 1      | 6             |
| Differentiation         |        | 0.1339        |
| Low                     | 12     | 27            |
| Moderate                | 20     | 18            |
| High                    | 5      | 5             |
| Tumor number            |        | 0.0187        |
| Single                  | 32     | 32            |
| Multiple                | 5      | 18            |
| Lung metastasis         |        | 0.1164        |
| Yes                     | 4      | 12            |
| No                      | 33     | 38            |
| HBsAg                   |        | 0.2247        |
| Negative                | 5      | 2             |
| Positive                | 32     | 48            |
| HBV infection           |        | 0.2247        |
| Absent                  | 5      | 2             |
| Present                 | 32     | 48            |

Differences between the groups were done by the Chi-square test.
HBsAg hepatitis B surface antigen, HBV hepatitis B virus.
developed using an enhanced chemiluminescence (ECL) detection Kit (Pierce Biotechnology, Rockford, IL, USA).

**Co-immunoprecipitation (Co-IP) and ubiquitination in vitro**

Co-IP was performed as described previously [20, 21]. Briefly, cold PBS was used to wash the cells for three times, and the cells were scraped into lysis buffer containing complete protease inhibitors and centrifuged at 14,000×g for 20 min at 4 °C. The supernatants were incubated with normal IgG or anti-HA tag antibody, and the immunocomplexes were then associated with Protein A-Sepharose. Anti-TRIM52 (1:500), anti-PPM1A (1:500), anti-HA-tag (1:500) and normal rabbit/mouse IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used for Western blot analysis. And the blots were immunoblotted by using anti-HA for ubiquitin.

**Nude mouse xenograft experiment**

Twelve nude mice (4–5 week-old BALB/c; Shanghai SLAC laboratory animal Co., Ltd., Shanghai, China) were housed in the animal facility at 25 °C with humidity of 60–70%. MHCC-97H cells (4 × 10⁶) transfected with pLKO.1-shRNA-TRIM52 or pLKO.1-scramble shRNA (NC) and MHCC-97L cells with pLVX-Puro-TRIM52 or pLVX-Puro (Vector), TRIM52 expression was measured by qRT-PCR (a, e) and Western blot analysis (b, c, f, g), and the cell proliferation was measured by CCK-8 assay (d, h). **P < 0.01 compared with corresponding NC or Vector.

**Results**

**TRIM52 is up-regulated in HCC tissues and cell lines**

IHC analysis on tissue microarrays containing 87 human HCC and adjacent non-tumor hepatic tissue samples found that TRIM52 was significantly up-regulated in the HCC tissues in comparison with the adjacent non-tumor hepatic tissues, specially between groups –, + and groups ++, +++. Median strongly and strongly positive TRIM52 staining was observed respectively in 48.3%
and 9.2% (8/87) of the HCC tissues (Fig. 1a and b). Moreover, the expression of TRIM52 in HCC based on GSE45436 database was further supported our findings on tissue microarrays (Fig. 1c). Then, we investigated the correlation between TRIM52 expression and clinicopathologic features of the 87 patients with HCC. TRIM52 expression was divided into two levels, low and high, based on the IHC analysis on tissue microarrays. As shown in Table 2, TRIM52 expression was correlated with tumor size, TNM stages and tumor number, but uncorrelated with age, sex, recurrence, pathologic stages, differentiation, lung metastasis, HBsAg and HBV infection.

qRT-PCR and Western blot analysis showed that TRIM52 was also up-regulated in HCC cell lines, including MHCC-97H and MHCC-97L cells, compared with normal human liver cell line LO2 (Fig. 1d–f). These data further suggest that TRIM52 is prominently up-regulated in HCC tissues and cell lines and that TRIM52 may facilitate HCC carcinogenesis.

TRIM52 up-regulation promotes HCC cell proliferation
In order to validate the effects of TRIM52 on HCC cell lines in vitro, shRNA targeting TRIM52 and scramble shRNA were cloned into the pLKO.1 lentiviral vector and transfected into MHCC-97H cells, respectively. Our results showed that there was a significant decrease in the mRNA and protein expression of TRIM52 in MHCC-97H cells with shRNA-TRIM52 transfection compared with scramble shRNA (NC) transfection (Fig. 2a–c). Furthermore, CCK-8 assay demonstrated that shRNA-TRIM52 significantly inhibited the proliferation of
MHCC-97H cells by 18.01, 37.67 and 48.33% at 24, 48 and 72 h compared with NC transfection, respectively (Fig. 2d).

Next, TRIM52 encoding sequence was cloned into pLVX-Puro for constructing the pLVX-Puro-TRIM52 expressing vector and transfected into MHCC-97L cells. Blank pLVX-Puro (Vector) was used as the negative control. As shown in Fig. 2e–g, TRIM52 up-regulation significantly increased the mRNA and protein expression of TRIM52 in MHCC-97L cells compared with blank pLVX-Puro (Vector) transfection. Furthermore, CCK-8 assay demonstrated that TRIM52 up-regulation significantly enhanced the proliferation of MHCC-97L cells by 16.03, 31.87 and 43.08% at 24, 48 and 72 h compared with Vector transfection, respectively (Fig. 2h). These results suggest that TRIM52 up-regulation promotes HCC cell proliferation.

**TRIM52 up-regulation promotes cell cycle progress, migration and invasion of HCC cells**

To further examine the role of TRIM52 in cell growth and motility of HCC cell lines, the cell cycle and migration as well as invasion were measured by flow cytometry and Transwell assay, respectively. We found that TRIM52 down-regulation significantly increased the number of MHCC-97H cells in G0-G1 phase by 34.55% and decreased the number of MHCC-97H cells in S and G2-M phases by 35.32 and 36.89%, compared with NC transfection, respectively, suggesting that TRIM52 down-regulation promoted MHCC-97H cell cycle arrest at G0-G1 phase (Fig. 3a). Moreover, Transwell assay demonstrated that TRIM52 down-regulation significantly inhibited MHCC-97H cell migration and invasion by 59.4 and 55.1% compared with NC transfection, respectively (Fig. 3b and c). Whereas TRIM52 up-regulation significantly increased the number of MHCC-97L cells in S phase by 75.35% and decreased the number of MHCC-97L cells in G0-G1 and G2-M phases by 20.40 and 9.05%, compared with Vector transfection, respectively (Fig. 3d). Furthermore, Transwell assay demonstrated that TRIM52 up-regulation significantly enhanced MHCC-97L cell migration and invasion by 31.5 and 56.5% compared with Vector transfection, respectively (Fig. 3e and f). These results suggest that TRIM52 up-regulation promotes cell cycle progress, migration and invasion of HCC cells.

**TRIM52 up-regulation regulates p21, MMP2, PPM1A, p-Smad2/3 and Smad2/3 expression in HCC cells**

p21, MMP2, PPM1A, p-Smad2/3 and Smad2/3 expression in HCC cells was also measured by Western blot analysis. As shown in Fig. 4a and b, TRIM52 up-regulation significantly enhanced the expression of p21, MMP2, PPM1A, p-Smad2/3 and Smad2/3 in MHCC-97H cells (a, b) and MHCC-97L cells (c, d) transfection as Fig. 2 described, the expression of p21, MMP2, PPM1A, p-Smad2/3 and Smad2/3 was measured by Western blot analysis. **P < 0.01 compared with corresponding NC or Vector**
down-regulation significantly promoted the protein expression of p21 and PPM1A, decreased MMP2 expression and induced Smad2/3 dephosphorylation in MHCC-97H cells compared with NC transfection. However, TRIM52 up-regulation significantly decreased the protein expression of p21 and PPM1A, increased MMP2 expression and induced Smad2/3 phosphorylation in MHCC-97L cells compared with Vector transfection (Fig. 4c and d). These results suggest that TRIM52 up-regulation regulates p21, MMP2, PPM1A, p-Smad2/3 and Smad2/3 expression in HCC cells.

TRIM52 down-regulation inhibits HCC cell growth, migration and invasion in vivo

To confirm the growth effect of TRIM52 in vivo, a xenograft tumor-bearing model was established by inoculating pLKO.1-shRNA-TRIM52 or pLKO.1-scramble shRNA (NC) transfected MHCC-97H cells into the nude mice. Thirty-three days after inoculation the mice were killed and the tumor weights of the pLKO.1-shRNA-TRIM52 transfected mice were significantly decreased compared with those of the NC mice (Fig. 5a). Tumors in the pLKO.1-shRNA-TRIM52 transfected mice grew much slower compared with those in the NC mice (Fig. 5b). Moreover, pLKO.1-shRNA-TRIM52 transfection significantly reduced hepatic injury and Ki67, p-Smad2/3 and MMP2 expression compared with NC transfection measured by hematoxylin-eosin (HE) staining and IHC (Fig. 5c). These results suggest that TRIM52 down-regulation inhibits HCC cell growth, migration and invasion in vivo.

TRIM52 interacts with PPM1A and TRIM52 down-regulation inhibits the ubiquitination of PPM1A

To elucidate the underlying mechanisms by which TRIM52 exerts its function in HCC carcinogenesis, we identified protein candidates that were functionally associated with TRIM52. PPM1A has been reported to inhibit the Smad2/3 signaling pathway and was significantly modulated by TRIM52 as above described.
PPM1A was therefore used for the following analysis. Co-IP assay demonstrated that TRIM52 interacted with PPM1A in MHCC-97H and MHCC-97L cells (Fig. 6a and b). TRIM52 down-regulation significantly inhibited the ubiquitination of PPM1A in 293T and MHCC-97H cells with pLKO.1-shRNA-TRIM52 or pLKO.1-scramble shRNA (NC) transfection. Meanwhile, both TRIM52 and PPM1A up-regulation significantly inhibited the proliferation of MHCC-97L cells at 24, 48 and 72 h compared with only pLVX-Puro-TRIM52 transfection (Fig. 7d). Transwell assay demonstrated that PPM1A up-regulation significantly inhibited MHCC-97L cell migration and invasion compared with Vector or pLVX-Puro-TRIM52 transfection, respectively. Meanwhile, both TRIM52 and PPM1A up-regulation significantly inhibited MHCC-97L cell migration and invasion compared with only pLVX-Puro-TRIM52 transfection (Fig. 7e and f). Our results also demonstrated that PPM1A up-regulation significantly increased p21 and PPM1A expression, decreased MMP2 expression and induced the dephosphorylation of Smad2/3 in MHCC-97L cells compared with Vector or pLVX-Puro-TRIM52 transfection, respectively. Meanwhile, both TRIM52 and PPM1A up-regulation significantly increased p21 and PPM1A expression, decreased MMP2 expression and induced the dephosphorylation of Smad2/3 in MHCC-97L cells compared with only pLVX-Puro-TRIM52 transfection (Fig. 7g and h). These results suggest that PPM1A overexpression inhibits TRIM52-mediated enhancement of cell proliferation, migration and invasion in HCC cells. PPM1A down-regulation may be an underlying mechanism of TRIM52 in HCC tumorigenesis.

**Discussion**

Cellular carcinogenesis is a multistep process involving multiple factors and genes, which is accompanied by changes in a variety of gene expression patterns and which in turn affects the proliferation, apoptosis and differentiation modulated by these genes. The occurrence and development of HCC is also a complex process with multiple genes and steps [22, 23], so it is of great theoretical and practical significance to elucidate the abnormal expression of genes in the process of HCC carcinogenesis. In the present study, we found that TRIM52 was up-regulated in HCC tissues and cell lines. TRIM52 expression was correlated with tumor size, TNM stages and tumor number. Up-regulation of TRIM52 promoted HCC cell proliferation, migration and invasion in vitro and cell growth in vivo through the ubiquitination of PPM1A. Moreover, PPM1A up-regulation inhibited TRIM52-mediated enhancement of HCC cell proliferation, migration and invasion.
A number of recent studies have focused on the function of TRIM proteins in HCC. TRIM3, TRIM16 and TRIM26 down-regulation contributes to poor prognosis in patients with HCC, suggesting the tumor suppressor function in HCC [24–26]. On the contrary, TRIM11 and TRIM31 function as oncogenes of HCC, showing up-regulation in HCC tissues and contributing to HCC cell proliferation and invasion [27, 28]. Except for up-regulation in HCC tissues and cell lines as well as enhancement of HCC cell proliferation reported in our recent study, no other effect has been reported in HCC carcinogenesis involving TRIM52 [19]. In line with the recent findings, our results also demonstrated TRIM52 up-regulation in the HCC tissues compared with the adjacent non-tumor hepatic tissues, and in HCC cell lines, including high metastatic MHCC-97H and low metastatic MHCC-97L, compared with normal human liver cell line LO2. TRIM52 up-regulation promoted HCC cell proliferation, migration and invasion in vitro, and down-regulation of TRIM52 inhibited HCC cell invasion, migration and proliferation, induced G0-G1 phase cell cycle arrest in vitro, and inhibited cell growth and Ki67, p-Smad2/3 and MMP2 expression in vivo.

Next, we studied the mechanism by which TRIM52 regulated HCC carcinogenesis. p21 is considered as a regulator of cell cycle progression at G1 through binding to and inhibiting the activity of cyclin D-CDK2 or cyclin D-CDK4 complexes [29]. Previous studies have indicated...
that MMP2 activation can enhance invasion, migration and metastasis of HCC [30, 31]. PPM1A down-regulation increased epithelial-to-mesenchymal transition (EMT) progress and invasion through increasing the activity of Smad2/3 signaling pathway in bladder cancer [32]. Simultaneous Smad2/3 phosphorylation was significantly associated with poor outcome of HCC patients after surgery [33] and increased HCC cell growth, invasion and migration [34, 35]. In this study, our results demonstrated that TRIM52 up-regulation inhibited p21 and PPM1A expression, increased MMP2 expression and induced Smad2/3 phosphorylation in HCC cells, which were reversed by TRIM52 down-regulation. These results suggest that these proteins may associate with TRIM52-mediated HCC cell proliferation, invasion and migration.

PPM1A inhibited the invasion and migration of HCC cells and induced the dephosphorylation of Smad2/3 [11–13], suggesting an opposite effect between PPM1A and TRIM52 in HCC. It therefore provides a hypothesis that TRIM52 might involve in HCC carcinogenesis through down-regulating PPM1A. Co-IP and ubiquitination assay confirmed that TRIM52 interacted with PPM1A and TRIM52 down-regulation inhibits the ubiquitination of PPM1A, which was similar to the regulatory mechanism of PPM1A in HBV-related HCC [13]. Moreover, down-regulation of PPM1A via promotion of proteasomal degradation and ubiquitination may result in HCC cell invasion and migration [12]. However, conclusive molecular mechanism by which TRIM52 enhances the ubiquitination of PPM1A need to be further studied. Our experiments demonstrated that PPM1A up-regulation inhibited TRIM52-mediated enhancement of the proliferation, migration and invasion of HCC cells.

Conclusions
In summary, we present a novel mechanism by which TRIM52 promotes HCC cell proliferation, migration and invasion through ubiquitination of PPM1A. Our study confirms an important function of TRIM52 in HCC development, indicating that strategies to enhance the activity and/or expression of PPM1A can be served as a therapeutic strategy for the prevention and treatment for HCC.

Abbreviations
BMP: Bone morphogenetic protein; CCK-B: Cell Counting Kit-8; Co-IP: Co-immunoprecipitation; DAB: Diaminobenzidine; DMEM: Dulbecco’s modified Eagle’s medium; ECL: Enhanced chemiluminescence; EMT: Epithelial-to-mesenchymal transition; FBS: Fetal bovine serum; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HE: Hematoxylin-eosin; HRP: Horseradish peroxidase; IHC: Immunohistochemistry; JEV: Japanese encephalitis virus; MMP2: Matrix metalloproteinase 2; NC: Negative control; PP2C: Protein phosphatase 2C; PPM1A: Protein phosphatase, Mg2+; p53: Tumor protein p53; Smad2/3: Signal transducer and activator of transcription; TRIM52: Tripartite motif-containing 52; TGF-β: Transforming growth factor-β; TUNEL: Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; Western blotting: Protein analysis method using sodium dodecyl sulfate polyacrylamide gel electrophoresis; shRNA: Short hairpin RNA; TGF-β: Transforming growth factor-β; TRIM: Tripartite motif; TRIM52: Tripartite motif containing 52.

Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81770589), the Natural Science Foundation of Shanghai (No. 17ZR1421500), the Scientific Research Fund of Shanghai Municipal Health and Family Planning Commission for Traditional Chinese Medicine (No. 2014Q019A) and the Medical Education Research Project of Shanghai Jiao Tong University School of Medicine (No. YB150712).

Authors’ contributions
YZ, XHC and GQZ designed the study. YZ and RT performed the experiments. YZ, RT and SSW collected the data. YZ, ZHT, YSY, XHC and GQZ analyzed and interpreted the data. YZ prepared the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Infectious Diseases, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai 200233, China. 2Department of Cardiology, Central Hospital of Minhang District, Shanghai 200119, China. 3Department of Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.

Received: 18 January 2018 Accepted: 21 May 2018

Published online: 13 June 2018

References
1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13.
2. Singh AG, Pillai A, Tio J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624.
3. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603–11.
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:764–73. e1
5. Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015;19:361–79.
6. Rong M, He R, Dang Y, Chen G. Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci. 2014;119:19–24.
7. Tsang FH, Au V, Lu WL, Shek FH, Liu AA, Luk JM, et al. Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2. Dig Dis Sci. 2014;59:2477–87.
8. Malki K, Uher R, Paya-Cano J, Binder E, Rietschel M, Zobel A, et al. Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants. Biol Psychiatry. 2011;69:366–5.
9. Ofek P, Ben-Meir D, Kariv-Inbal Z, Oren M, Lavi S. Cell cycle regulation and p53 activation by protein phosphatase 2C alpha. J Biol Chem. 2003;278:14299–305.
10. Duan X, Liang YY, Feng XH, Lin X. Protein serine/threonine phosphatase PPM1A dephosphorylates Smad1 in the bone morphogenetic protein signaling pathway. J Biol Chem. 2006;281:36526–32.
11. Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, et al. PPMT1A functions as a Smad phosphatase to terminate TGFβ signaling. Cell. 2006;125:915–28.
12. Zhou Y, Zhao Y, Gao Y, Hu W, Qu Y, Lou N, et al. Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPMT1A ubiquitination and degradation. J Exp Clin Cancer Res. 2017;36:42.
13. Liu Y, Xu Y, Ma H, Wang B, Xu L, Zhang H, et al. Hepatitis B virus X protein amplifies TGF-β promotion on HCC motility through down-regulating PPMT1A. Oncotarget. 2016;7:33125–35.
14. Lim SD, Hwang JG, Han AR, Park YC, Lee C, Ok YS, et al. Positive regulation of SMAD4 expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway. Oncotarget. 2016;7:5055–68.
15. Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene. 2011;30:1108–16.
16. Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42:297–311.
17. Fan W, Wu M, Qian S, Zhou Y, Chen H, Li X, et al. TRIM52 inhibits Japanese encephalitis virus replication by degrading the viral NS2A. Sci Rep. 2016;6:33698.
18. Zhang Y, Wu SS, Chen XH, Tang ZH, Yu YS, Zang GQ. Tripartite motif containing 52 (TRIM52) promotes cell proliferation in hepatitis B virus-associated hepatocellular carcinoma. Med Sci Monit. 2017;23:5202–10.
19. Hosono M, Shioda Y, Hirano T, Ishitani Y, Murakami K, Sagata T. Interaction of calsH-dependent activator protein for secretion 1 (CAPS1) with septin family proteins in mouse brain. Neurosci Lett. 2016;617:232–5.
20. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. Tripartite motif 16 inhibits cell invasion and migration through ubiquitination of TSC1-TSC2 complex. Oncogene. 2018;37:478–92.
21. Chung GE, Yoon JH, Myung SJ, Lee JH, Lee SH, Lee SM, et al. High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. Oncol Rep. 2010;23:113–9.
22. Jiang R, Xie Y, Ji L, Deng L, Zhao L, Shi J, et al. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. Int J Cancer. 2010;126:1263–74.
23. Chao J, Zhang XF, Pan QZ, Zhao JJ, Jiang SS, Wang Y, et al. Decreased expression of TRIMS1 is associated with poor prognosis in patients with primary hepatocellular carcinoma. Med Oncol. 2014;31:102.
24. Li L, Dong L, Ou X, Jin S, Lv X, Tan G. Tripartite motif 16 enhances hepatocellular carcinoma cell migration and invasion. Int J Oncol. 2016;48:1639–49.
25. Wang Y, He D, Yang L, Wen B, Dai J, Zhang Q, et al. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and promotes disease progression by inducing cell cycle arrest. Oncol Rep. 2016;35:1639–49.
26. Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y, et al. TRIM31 is upregulated in hepatocellular carcinoma and its downregulation contributes to worse prognosis. Biochem Biophys Res Commun. 2015;463:458–65.
27. Zhai Z, Xu C, Zhang X, Huang L, Zheng C, Chen H, et al. TRIM11 upregulation contributes to proliferation, invasion, and EMT of hepatocellular carcinoma cells. Oncol Rep. 2017;37:691–9.
28. Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y, et al. TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex. Oncogene. 2018;37:478–88.
29. Choi EJ. Hesperetin induced G1-phase cell cycle arrest in human breast cancer MCF-7 cells: involvement of CDK4 and p21. Nutr Cancer. 2007;59:115–9.
30. Chen JS, Huang XH, Wang Q, Chen XL, Fu XH, Tan HX, et al. FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis. 2010;27:71–82.
31. Sze KM, Wong KL, Chu GK, Lee JM, Yau TO, Ng IO. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Skp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology. 2011;53:1558–69.
32. Geng J, Fan J, Qian Q, Zhang X, Zhang Y, Ju J, et al. Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β5/Smad signaling pathway. Oncotarget. 2014;5:700–13.
33. Hernanda PY, Chen K, Das AM, Sideras K, Wang W, Li J, et al. SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene. 2015;34:5055–68.